Chen Wei-An, Chen Yu-Hsin, Hsieh Chiao-Yun, Hung Pi-Fang, Chen Chiao-Wen, Chen Chien-Hung, Lin Jung-Lee, Cheng Ting-Jen R, Hsu Tsui-Ling, Wu Ying-Ta, Shen Chia-Ning, Cheng Wei-Chieh
Genomics Research Center, Academia Sinica 128, Section 2, Academia Road Taipei 11529 Taiwan
Department of Chemistry, National Cheng-Kung University 1, University Road Tainan 701 Taiwan.
Chem Sci. 2022 Apr 19;13(21):6233-6243. doi: 10.1039/d1sc05894k. eCollection 2022 Jun 1.
Modulation of -glycosylation using human Golgi α-mannosidase II (α-hGMII) inhibitors is a potential anticancer approach, but the clinical utility of current α-hGMII inhibitors is limited by their co-inhibition of human lysosomal α-mannosidase (α-hLM), resulting in abnormal storage of oligomannoses. We describe the synthesis and screening of a small library of novel bicyclic iminosugar-based scaffolds, prepared natural product-inspired combinatorial chemistry (NPICC), which resulted in the identification of a primary α-hGMII inhibitor with 13.5-fold selectivity over α-hLM. Derivatization of this primary inhibitor using computation-guided synthesis (CGS) yielded an advanced α-hGMII inhibitor with nanomolar potency and 106-fold selectivity over α-hLM. studies demonstrated its -glycan modulation and inhibitory effect on hepatocellular carcinoma (HCC) cells. studies confirmed its encouraging anti-HCC activity, without evidence of oligomannose accumulation.
使用人高尔基体α-甘露糖苷酶II(α-hGMII)抑制剂调节N-糖基化是一种潜在的抗癌方法,但目前的α-hGMII抑制剂的临床应用受到其对人溶酶体α-甘露糖苷酶(α-hLM)的共同抑制的限制,导致低聚甘露糖异常储存。我们描述了一个基于新型双环亚氨基糖支架的小型文库的合成和筛选,该文库采用天然产物启发的组合化学(NPICC)制备,结果鉴定出一种对α-hLM具有13.5倍选择性的主要α-hGMII抑制剂。使用计算指导合成(CGS)对该主要抑制剂进行衍生化,得到一种具有纳摩尔效力且对α-hLM具有106倍选择性的先进α-hGMII抑制剂。研究证明了其对N-聚糖的调节作用以及对肝癌(HCC)细胞的抑制作用。研究证实了其令人鼓舞的抗HCC活性,且没有低聚甘露糖积累的证据。